Research programme: Staphylococcus aureus vaccine and antibody therapeutics - Absynth

Drug Profile

Research programme: Staphylococcus aureus vaccine and antibody therapeutics - Absynth

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Absynth Biologics
  • Class Bacterial vaccines; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Staphylococcal infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Staphylococcal-infections in United Kingdom (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Staphylococcal-infections(Prevention) in United Kingdom (Parenteral)
  • 03 Sep 2010 Absynth Biologics entered into a licensing and collaboration agreement with MorphoSys for a Staphylococcus aureus vaccine and Antibody therapeutics programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top